Breaking News Instant updates and real-time market news.

FNSR

Finisar

$25.64

0.38 (1.50%)

, COST

Costco

$180.06

-1.61 (-0.89%)

09:40
06/16/17
06/16
09:40
06/16/17
09:40

Unusually active option classes on open June 16th

Unusual total active option classes on open include: Finisar (FNSR), Costco (COST), Nike (NKE), Wal-Mart (WMT), Oclaro (OCLR), CVS Health (CVS), Amazon (AMZN), EEM (EEM), Powershares QQQ (QQQ), and Valeant (VRX).

FNSR

Finisar

$25.64

0.38 (1.50%)

COST

Costco

$180.06

-1.61 (-0.89%)

NKE

Nike

WMT

Wal-Mart

OCLR

Oclaro

$9.54

-0.19 (-1.95%)

CVS

CVS Health

AMZN

Amazon.com

$964.17

-12.3 (-1.26%)

EEM

MSCI Emerging Markets Index

QQQ

PowerShares QQQ Trust

$139.13

-0.62 (-0.44%)

VRX

Valeant

  • 19

    Jun

  • 19

    Jun

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 29

    Jun

  • 24

    Aug

FNSR Finisar
$25.64

0.38 (1.50%)

06/16/17
STFL
06/16/17
NO CHANGE
STFL
Finisar fundamentals likely to bottom next month, says Stifel
After Finisar reported lower than expected Q4 revenue and provided weaker than expected Q1 guidance, Stifel analyst Patrick Newton blamed several factors for the weakness, including the company's China business and 10G softness. However, the analyst says that the stock reflects the China weakness while the company's fundamentals will probably bottom next month. He keeps a $33 price target and a Buy rating on the shares.
06/16/17
CHLM
06/16/17
NO CHANGE
Target $38
CHLM
Buy
Finisar upside drivers all coming in second half, says Craig-Hallum
Craig-Hallum analyst Richard Shannon said that despite Finisar's below consensus guidance for next quarter, the company's commentary with its Q4 report offered reasons for optimism in the second half of 2017 from a number of areas, including 3D sensing, 100G Datacom, ROADM line cards and Analog Coherent Optics. He sees a favorable risk/reward in the shares at current levels given expectations for accelerating sales growth and improving margins and keeps a Buy rating and $38 target on Finisar.
06/16/17
JEFF
06/16/17
NO CHANGE
Target $34
JEFF
Buy
Finisar's business to improve from here, says Jefferies
Jefferies analyst James Kisner says Finisar's (FNSR) weaker than expected Q1 outlook was widely expected and that the company's expectations to ship tens of millions of units for 3D sensing in the October quarter is important. In a post-earnings research note titled "Who Cares About Q1 Guidance...Here Comes 3D Sensing! Reiterate Buy," Kisner argues Finisar's business will improve from here. He believes the talk around 3D sensing is also positive for Lumentum (LITE). The analyst keeps a Buy rating on Finisar with a $34 price target.
06/16/17
PIPR
06/16/17
NO CHANGE
Target $32
PIPR
Overweight
Finisar 3D sensing comments to drive shares higher, says Piper Jaffray
Piper Jaffray analyst Troy Jensen says that while Finisar's April quarter and July quarter guidance came in below consensus, the company's comments regarding volume 3D sensing orders starting in the October quarter will likely drive the stock higher. He believes Finisar's risk/reward "looks compelling" and reiterates an Overweight rating on the shares with a $32 price target.
COST Costco
$180.06

-1.61 (-0.89%)

04/21/17
LEHM
04/21/17
UPGRADE
Target $185
LEHM
Overweight
Costco upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Karen Short upgraded Costco Wholesale (COST) to Overweight after her survey of 800 customers indicated more than 80% of them go to Costco stores specifically for food. This suggests the company is "very protected" from Amazon (AMZN), Short tells investors in a research note. The analyst expects Costco's traffic to accelerate amid easing comparisons into the second half of the year. Short also sees the potential for a special dividend from a tax break on foreign cash repatriation. She raised her price target for the shares to $185 from $170.
05/26/17
FBCO
05/26/17
NO CHANGE
Target $195
FBCO
Outperform
Costco price target raised to $195 after 'bounce-back quarter' at Credit Suisse
Credit Suisse analyst Edward Kelly noted that Costco followed up a "disappointing" Q2 performance with a "much better" Q3, noting that its new card continued to contribute while core merchandise margin also improved and fuel turned into a tailwind. The quarterly report was "clearly positive," comparisons remain fairly easy in the near-term and Costco's performance is notable given the landscape of other "structurally challenged retail names," which suggests the stock could still have legs, Kelly tells investors. He raised his price target to $195 from $187 and keeps an Outperform rating on Costco shares.
05/01/17
CLVD
05/01/17
NO CHANGE
CLVD
Costco April sales slightly softer versus March, says Cleveland Research
Cleveland Research said Costco's April sales are slightly softer versus March ex-Easter shift, but still in line with channel expectations. The firm said Costco has been focused on price/value recently, which could incrementally pressure gross margins.
04/21/17
04/21/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Costco (COST) upgraded to Overweight from Equal Weight at Barclays with analyst Karen Short citing a survey by the firm where results showed analytically that Costco (COST) is "very protected" from Amazon (AMZN). 2. CSX (CSX) was upgraded to Buy from Hold at Aegis and to Outperform from Market Perform at Raymond James. 3. Gigamon (GIMO) upgraded to Buy from Hold at Stifel with analyst Patrick Newton citing valuation and his belief that the company has a number of potential positive catalysts, including the 100G upgrade cycle at T-Mobile (TMUS), in-line SSL decryption, and the potential for reduced competition from Ixia (XXIA). 4. Skechers (SKX) upgraded to Buy from Neutral at B. Riley with analyst Jeff Van Sinderen citing "strong" international growth and worldwide comps following the company's better than expected first quarter results. The analyst raised his price target for the shares to $32 from $28. 5. Quest Diagnostics (DGX) upgraded to Outperform from Market Perform at Raymond James with analyst Nicholas Jansen saying Quest has delivered two strait quarters of high single digit adjustment EBIT growth and sees room for sustained mid-to-high single digit growth driven by improved commercial execution, strengthening health system relationships and outreach deals, and invigorate programs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NKE Nike

06/16/17
BARD
06/16/17
NO CHANGE
Target $62
BARD
Outperform
Nike restructuring a replay of 2009, suggests buying opportunity, says Baird
Baird analyst Jonathan Komp noted Nike has undergone multiple restructurings, stating that the current one appears to be a replay of its 2009 strategy, which resulted in a very strong multi-year stretch of outperformance for the stock. The analyst said the playbook suggest a compelling buying opportunity post Q4 earnings. Komp maintained his Outperform rating and $62 price target on Nike shares.
06/01/17
PIPR
06/01/17
NO CHANGE
Target $50
PIPR
Neutral
Piper 'firmly' believes too early to buy Nike shares
Piper Jaffray analyst Erinn Murphy believes Nike's innovation pipeline "has paused" while competition "remains fierce." The analyst "firmly" believes it remains too early to buy Nike shares. To reflect further gross margin pressures and currency moves, the analyst lowered her FY18 earnings estimate to $2.40 from $2.44 and price target to $50 from $51. Murphy expects Nike management, in due course, will lower their long-term targets. She keeps a Neutral rating on the shares.
06/13/17
ARGS
06/13/17
DOWNGRADE
ARGS
Hold
Foot Locker downgraded to Hold from Buy at Argus
Argus analyst John Staszak downgraded Foot Locker (FL) based on weakening demand for Nike (NKE) footwear. The analyst says that Nike footwear generates more than two-thirds of Foot Locker's revenue, and he thinks that the retailer will have difficulty reaching 5% comp sales growth in the second half of fiscal 2018.
06/16/17
JPMS
06/16/17
DOWNGRADE
Target $58
JPMS
Neutral
Nike downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Matthew Boss downgraded Nike to Neutral and lowered his price target for the shares to $58 from $61. The footwear giant closed yesterday down 3%, or $1.76, to $52.90. The analyst's work suggests Nike's sales in North America are likely to get worse before getting better. The company changes announced this week will take time, Boss tells investors in a research note. The analyst, however, is "encouraged" by management's cost reductions and "forward thinking initiatives."
WMT Wal-Mart

05/19/17
BMOC
05/19/17
UPGRADE
BMOC
Market Perform
Wal-Mart upgraded on outlook improvement at BMO Capital
As noted earlier, BMO Capital upgraded Wal-Mart to Market Perform from Underperform. Analyst Wayne Hood says the outlook of the company's sales and transaction growth has improved in the wake of its Q1 results. However, he adds that the retailer continues to face "many challenges." Target to $80 from $63.
05/19/17
COWN
05/19/17
NO CHANGE
Target $83
COWN
Outperform
Wal-Mart e-commerce business remains in early innings, says Cowen
Cowen analyst Oliver Chen said Wal-Mart continues to execute in a difficult retail environment. He noted e-commerce sales were up 63% during the quarter and he believes they remain in the early innings. Chen believes Wal-Mart will continue to innovate and execute and thus reiterated his Outperform rating and $83 price target on Wal-Mart shares.
05/31/17
BARD
05/31/17
NO CHANGE
Target $85
BARD
Outperform
Wal-Mart e-commerce coming into focus, says Baird
Baird analyst Peter Benedict noted upcoming Wal-Mart events that will give the company the chance to provide a baseline on its e-commerce operation. The analyst noted the operation is beginning to show some encouraging signs despite profitability remaining in flux. He noted the upcoming shareholder's meeting and the Baird conference as two opportunities that are imminent. Benedict reiterated his Outperform rating and $85 price target on Wal-Mart shares.
06/15/17
NOMU
06/15/17
NO CHANGE
NOMU
Amazon.com price target raised to $1,100 from $975 at Nomura Instinet
Nomura Instinet analyst Anthony DiClemente says that Amazon's (AMZN) current valuation is "reasonable." The analyst says that, assuming the cloud business is worth $220B, based on a 2020 multiple similar to that given Microsoft (MSFT), while its Prime video business is worth $8B, or 12% of Netflix's (NFLX) current valuation, and its advertising business is worth $27B, or double his estimate of Snap's (SNAP) total valuation, the company's e-commerce business is only being valued at about $210B at current levels. Noting that Wal-Mart (WMT) is currently valued at $280B, the analyst says that Amazon's valuation "is not excessively strencthed." DiClemente raised his 2020 EV/EBITDA multiple for the cloud business to 14x from 13.5x, noting that SAP (SAP), Oracle (ORCL) and Microsoft (MSFT) all had higher multiples at similar points in their histories. The analyst raised his target multiple for Amazon's North America e-commerce business to 13x from 12x, which he says is in-line with Wal-Mart's mean multiple from 1992-2001. He raised his price target on Amazon to $1,100 from $975 and keeps a Buy rating on the stock.
OCLR Oclaro
$9.54

-0.19 (-1.95%)

05/17/17
RSBL
05/17/17
INITIATION
Target $12
RSBL
Buy
Oclaro initiated with a Buy at Rosenblatt
Rosenblatt analyst Jun Zhang started Oclaro earlier with a Buy rating and $12 price target.
05/22/17
JEFF
05/22/17
NO CHANGE
JEFF
Buy
China Mobile build-out good news for Oclaro, says Jefferies
Jefferies analyst James Kisner points out that China Mobile last night selected vendors for the build-out of its Packet Transport Network, with 70% going to ZTE and the balance to Huawei. The news is particularly good for Oclaro (OCLR), which has significant exposure to ZTE, Kisner tells investors in a research note. It also bodes well for a recovery of telecom and networking equipment demand in China, which is positive for Finisar (FNSR) and Lumentum (LITE), the analyst adds. Kisner has Buy ratings on all three stocks.
05/22/17
RSBL
05/22/17
NO CHANGE
RSBL
China Telecom has begun work on Metro upgrade plan, says Rosenblatt
Rosenblatt Securities said China Telecom (CHA) has begun work on its Metro upgrade plan and the firm believes it will release tenders for both provincial and Metro in the timeframe of September to October. Companies in the optical equipment space that could benefit from China's upgrade cycle include Oclaro (OCRL), Finisar (FNSR), Lumentum (LITE), NeoPhotonics (NPTN), Acacia Communications (ACIA) and Viavi (VIAV).
06/12/17
NEED
06/12/17
NO CHANGE
Target $14
NEED
Strong Buy
Oclaro tone sounded 'more cautious' at recent meeting, says Needham
Needham analyst Alex Henderson keeps a Strong Buy rating and $14 price target on Oclaro after hosting a recent meeting with the company's management, though he notes that the company's leaders sounded "modestly more cautious" on the outlook for China. Oclaro reiterated it believes China will be flat to down sequentially throughout 2017 and also is stating China could be flat to down in 2018, according to Henderson, who added that Oclaro sounded more cautious than the other optical space players.
CVS CVS Health

05/05/17
LEER
05/05/17
NO CHANGE
Target $90
LEER
Outperform
CVS Health should retain Aetna, says Leerink
Leerink analyst David Larsen remains positive on CVS Health (CVS) following the company's earnings call. The analyst believes that as investors look to 2018, CVS will have major headwinds behind it, including volume loss from narrow networks and promotion rationalization in retail. Larsen sees a "significant positive catalyst" in a potential Anthem (ANTM) win later this year, and does not believe there is real risk to the Aetna (AET) business. He reiterates an Outperform rating and $90 price target on CVS' shares.
05/11/17
CLVD
05/11/17
UPGRADE
CLVD
Buy
Aetna upgraded to Buy from Neutral at Cleveland Research
Cleveland Research analyst Steve Willoughby upgraded Aetna (AET) to Buy saying recent research indicates an expanding relationship with CVS likely beginning on January 1, 2018. The analyst believes an enhanced partnership with CVS will generate significant savings for Aetna and support stronger 2018 MA growth, on top of additional earnings growth of 2-7%.
06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
06/08/17
JPMS
06/08/17
NO CHANGE
JPMS
Overweight
Humana takeover still likely, $300 bid possible, says JPMorgan
After hosting investor meetings with management, JPMorgan analyst Gary Taylor says a possible sale of Humana (HUM) is still likely. The company's Medicare Advantage assets are coveted by every other publicly traded health plan and likely pharmacy benefit managers/drug stores, Taylor tells investors in a research note. He thinks Humana management is well prepared to discuss the possibilities of both health plan and PBM or drug store integration. The analyst continues to believe Cigna (CI) is the most plausible candidate, presuming a simultaneous sale of HealthSpring, to buy Humana. He sees the potential for a $250-$300 per share bid. Humana closed yesterday up 25c to $233.75. Along with Cigna, publicly traded health plans include Aetna (AET), Anthem (ANTM) and UnitedHealth (UNH). Express Scripts (EXRX) and CVS Health (CVS) are pharmacy benefit managers.
AMZN Amazon.com
$964.17

-12.3 (-1.26%)

06/16/17
KEYB
06/16/17
NO CHANGE
KEYB
Microsoft to benefit from cloud expansion, says KeyBanc
KeyBanc says that spending on the cloud could triple to $239B within five years, and the firm says that Microsoft (MSFT) "has the most to gain," as it thinks that the company is poised to surpass Amazon (AMZN) to become the sector leader. KeyBanc keeps a $78 price target and an Overweight rating on Microsoft.
06/16/17
FBRC
06/16/17
NO CHANGE
Target $111
FBRC
Outperform
Carter's positioned for multiple expansion, says FBR Capital
FBR Capital analyst Susan Anderson says shares of Carter's (CRI) have been pressured by concerns over exposure to department stores. The analyst, however, believes the department store weakness is more than offset with Amazon/Skip Hop growth. Further, the analyst thinks the company's Q2 is "trending significantly better" than Q1 based on "solid spendtrend data" for children's. She expects Carter's to see multiple expansion and keeps an Outperform rating on the shares with a $111 price target.
06/15/17
06/15/17
NO CHANGE

FANG fundamentals still strong but stocks may moderate, says Canaccord
Canaccord analyst Michael Graham noted the FANG stocks - Facebook (FB),Amazon (AMZN), Netflix (NFLX), and Google parent Alphabet (GOOG) - outpaced the S&P by a great deal and he feels even though fundamentals remain strong, the shares' momentum may begin to moderate. Graham believes most of the growth opportunities in tech remain with the FANG group but he believes valuations are quite reasonable. He downgraded Alphabet to Hold from Buy and believes that Amazon is the one to own long-term.
EEM MSCI Emerging Markets Index

QQQ PowerShares QQQ Trust
$139.13

-0.62 (-0.44%)

VRX Valeant

06/09/17
WELS
06/09/17
NO CHANGE
WELS
Outperform
Wells says Valeant's focus on EBITDA ignores rising borrowing costs
After Valeant Pharmaceuticals issued a regulatory filing with financial data for its just sold iNova Pharmaceuticals unit, Wells Fargo analyst David Maris says that while the company is executing deals and reducing absolute debt, "leverage seems to be relatively unchanged." Valeant's focus on EBITDA versus earnings is to have investors "ignore the impact of increased borrowing costs and any impact from potential dilutive equity based financing," Maris tells investors in a research note. Valeant has indicated an equity raise is not off the table, the analyst adds. He has an Underperform rating on the stock with a $9 price target. Valeant in afternoon trading is down 26c to $13.00.
06/14/17
RODM
06/14/17
NO CHANGE
Target $6
RODM
Buy
EyeGate price target lowered to $6 from $10 at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju lowered his price target for EyeGate Pharmaceuticals (EYEG( to $6 after the company granted a subsidiary of Valeant Pharmaceuticals (VRX) exclusive commercial and manufacturing rights to the EyeGate II Delivery System and EGP-437 combination product for treatment of post-operative pain and inflammation in ocular surgery patients. The analyst views the development, along with the top-line data from the first-in-human pilot trial of ocular bandage gel in patients with large corneal epithelial defects, as positive developments and raised his valuation of the company to $112M from $80M. His lowered target reflects higher shares outstanding. Selvaraju reiterates an Outperform rating on EyeGate.
06/16/17
CANT
06/16/17
INITIATION
Target $18
CANT
Overweight
Valeant initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Valeant Pharmaceuticals with an Overweight rating and $18 price target. The analyst believes Valeant can reduce its debt to manageable levels over the medium term and thinks new management can post earnings upside in 2019 and beyond. The analyst also thinks the negative media attention placed on the company has reduced significantly from a year ago.
06/08/17
WELS
06/08/17
NO CHANGE
Target $9
WELS
Underperform
Valeant's iNova sale to have minimal impact on debt, says Wells Fargo
Wells Fargo analyst David Maris believes Valeant Pharmaceuticals' sale of iNova Pharmaceuticals for $930M in cash, while possibly "slightly deleveraging," will not have much of an impact on the company's total debt of $28.5B, particularly if the gross proceeds are reduced by tax or other payments. The analyst notes that press reports in September suggested iNova could fetch more than $1B. Maris keeps an Underperform rating on Valeant with a $9 price target. The shares in morning trading are up 8% to $13.18.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.